Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Multiple Myeloma Side Effects- DVT, VTE aka Blood Clots

Share Button

It is a well-known fact that chemotherapy can induce endothelial dysfunction and contribute to cardiovascular side effects (in MM), with both venous and arterial thromboembolism (blood clot) associated with cisplatin

I was diagnosed with multiple myeloma (MM) in early ’94. I began induction therapy (VAD) in March of ’95 and developed a MM side effect called a deep vein thrombosis (DVT-blood clot) about three weeks after I began my first course of chemotherapy.  A VTE, DVT, or a blood clot can be deadly and expensive.

My blood clot became “chronic” or permanent and I have learned to live with it. Cancer patients call life like this “the new normal.”

As the studies and articles talk about below, conventional oncology has known about the prevalence and costs, both financial and social, of MM side effect, both VTE and DVT for years and yet have not solved this problem.

The standard-of-care for my chronic DVT, when I was first diagnosed in ’99, was blood-thinning drugs such as Coumadin (warfarin) to be taken for the rest of my life. There are well-documented long-term side effects from taking these drugs and I chose to manage my chronic blood-clot alternatively.

I take these supplements daily to manage my chronic blood clot:

1) Nattokinase

2) systemic enzymes ( Wobenzym N)

3) Omega 3 Fatty Acids (Fish Oil)

4) Curcumin

For more information about identifying and managing collateral damage from conventional therapies, scroll down the page, post a question or comment and I will reply to you ASAP.

Thank you,

David Emerson

  • Myeloma Survivor
  • MM Coach
  • Director PeopleBeatingCancer

Recommended Reading:

Real-World Costs of VTE in Cancer Patients

The risk of VTE at 3.5 months following chemotherapy initiation is about 4% in these 2 common cancer types,(breast and prostate cancer) with the cumulative risk almost doubling at 12 months,” Dr. Kuderer reported. “VTE development is associated with a significant economic burden in terms of healthcare expenditure.”

Thromboprophylaxis in Cancer Patients: Needs Rethink

“Considering that 60% of venous thromboembolism cases are related to hospitalization, that 20% of venous thromboembolism occurs in oncology patients, and that venous thromboembolism is associated with increased in-hospital mortality, it is disheartening that good quality research has not been done to address in-hospital thromboprophylaxis in patients with cancer…

The new study, a prospective, cross-sectional study involving 775 patients with cancer hospitalized in 5 academic medical centers, found that thromboprophylaxis was used in 74% of patients, and 50.6% received pharmacologic thromboprophylaxis. Unfractionated heparin was ordered in 62.0% of uses (given tid in 94% of patients), enoxaparin in 37.8%…”

Cisplatin Linked to Higher Risk for VTEs

“”It is a well-known fact that chemotherapy can induce endothelial dysfunction and contribute to cardiovascular side effects, with both venous and arterial thromboembolism associated with cisplatin,” said Grace Dy, MD,..”

The Most BioAvailable Curcumin Formulas

“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”

A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.

I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.

The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.

The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.


CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.[1]

Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers.

“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.

The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.

Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.

Based on the published reports,

exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”

According to Consumerlab.com:

“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”

Leave a Comment:

Add Your Reply